Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Terns Pharmaceuticals ( (TERN) ) has shared an announcement.
On February 20, 2025, Carl Gordon resigned from the Board of Directors of Terns Pharmaceuticals, and Robert Azelby was appointed as a new member and a part of the Compensation Committee. Mr. Azelby, a seasoned executive with extensive experience in the biopharmaceutical industry, is expected to bring strategic and operational expertise, particularly in advancing Terns’ oncology programs, such as TERN-701 for chronic myeloid leukemia, into late-stage studies.
More about Terns Pharmaceuticals
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule product candidates for serious diseases such as oncology and obesity. The company’s portfolio includes several clinical stage development programs, such as an allosteric BCR-ABL inhibitor and a GLP-1 receptor agonist.
YTD Price Performance: -26.10%
Average Trading Volume: 1,817,446
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $350.8M
Learn more about TERN stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue